Apellis Pharmaceuticals, Inc.
APLS
$23.19
-$0.30-1.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 754.65M | 775.84M | 781.37M | 715.22M | 628.79M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 754.65M | 775.84M | 781.37M | 715.22M | 628.79M |
| Cost of Revenue | 440.76M | 461.16M | 445.29M | 417.28M | 396.98M |
| Gross Profit | 313.89M | 314.68M | 336.08M | 297.94M | 231.80M |
| SG&A Expenses | 503.95M | 500.89M | 501.05M | 521.27M | 544.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 944.71M | 962.06M | 946.35M | 938.55M | 941.92M |
| Operating Income | -190.06M | -186.22M | -164.98M | -223.33M | -313.13M |
| Income Before Tax | -226.49M | -222.35M | -196.72M | -247.80M | -330.95M |
| Income Tax Expenses | 1.69M | 1.33M | 1.16M | 2.30M | 1.94M |
| Earnings from Continuing Operations | -228.17 | -223.68 | -197.88 | -250.10 | -332.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -228.17M | -223.68M | -197.88M | -250.10M | -332.89M |
| EBIT | -190.06M | -186.22M | -164.98M | -223.33M | -313.13M |
| EBITDA | -188.26M | -184.42M | -163.18M | -221.51M | -311.30M |
| EPS Basic | -1.82 | -1.79 | -1.60 | -2.04 | -2.74 |
| Normalized Basic EPS | -1.13 | -1.10 | -0.98 | -1.25 | -1.69 |
| EPS Diluted | -1.82 | -1.79 | -1.60 | -2.04 | -2.74 |
| Normalized Diluted EPS | -1.13 | -1.10 | -0.98 | -1.25 | -1.69 |
| Average Basic Shares Outstanding | 500.23M | 498.11M | 495.62M | 492.33M | 488.39M |
| Average Diluted Shares Outstanding | 500.23M | 498.11M | 495.62M | 492.33M | 488.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |